New York, August 19, 2011--Innovations in needle-free drug delivery will become a must as biological drugs become increasingly sophisticated and the traditional delivery methods are no longer suitable, according to Kalorama Information. The healthcare market research publisher estimates that needle-free drug delivery methods--which include patches, edible vaccines, pen injectors and more--will likely see a significant increase in revenues, with annual growth averaging 15.1% from 2011 through 2016 to reach $6.2 billion, according to their new report on these systems.
Drug delivery technology has come into its own in the last 25 years. Initially seen as merely a medium for a drug, it is now viewed as a tool for modifying the pharmacologic properties of drugs, improving methods of delivery, and targeting drugs to specific locations. Progress in the fields of microencapulation, polymer technology and nanoparticles now allow scientists to prolong the effect of drugs with short half-lives, and companies are developing a new generation of sophisticated delivery systems.
Arizona Biodesign Institute in Tempe is in the vanguard of the movement toward edible vaccines. The institute has concluded three early-stage clinical trials using potatoes bearing vaccines against hepatitis B, E. coli and the Norwalk Virus. Similarly, researchers at Japan's National Institute of Agrobiological Sciences continue to develop an edible vaccine produced in genetically modified rice.
"The line between drug delivery and drug substance will become increasingly elusive in the near future, as researchers work to improve drug properties through drug design and molecular modeling," notes Bruce Carlson, Kalorama Information's publisher. "In the next decade, drug delivery technologies will be a focal point of competition and the success of specific drugs will be tied to innovative delivery techniques, which will enable the targeting that will exploit the clinical properties of a new generation of drugs."
Competition in the segment has already increased over the past 10 years, with top delivery technology companies such as Antares, Bioject, MediImmune and Zogenix taking a leading role. Bioject offers several proprietary delivery technologies, including Biojector 2000, Cool.click, Injex, Serojet, and Vitajet, which are used in a wide range of applications including insulin, vaccine, and hormone drug delivery. Zogenix offers the Intraject system, which is a pre-filled, disposable, needle-free injector for the delivery of a wide range of liquid drugs, therapeutic proteins, and vaccines.
More information about the report, Needle-Free Drug Delivery: The Market for Alternatives to Needle-Based Systems for Vaccine and Biologics, is available from Kalorama Information's website. This title includes a comprehensive market overview, descriptions of products on the market and in development, market estimates and forecasts, company profiles, trends in the industry and much more.
About Kalorama Information
Questions?Contact a research specialist >